Because of the high visibility of drug abuse lately the FDA has extra interest in the ART tech drugs and will expedite their response to the application and review.
This states the obvious. That the clock does not begin until the FDA starts it? We know that...So, what is your point? More importantly, how does it alter the outcome of the successful P-3 that is the basis for the filing?